Preview

Siberian journal of oncology

Advanced search

EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN

https://doi.org/10.21294/1814-4861-2019-18-4-27-33

Abstract

Purpose of the study: to assess the efficacy and safety of morphine hydrochloride in the form of 10 mg filmcoated tablets and 1 % solution for injection in cancer patients with chronic pain syndrome of strong intensity.

Material and Methods. The study included 110 cancer patients with chronic pain syndrome of strong intensity. The study was conducted in compliance with the principles of the Helsinki Declaration, ICH GCP, GOST R 52379-2005, as well as other Russian laws regulating the conduct of clinical trials and work with opioid analgesics. Patients were randomized at a 1:1 ratio. Group I received 10 mg film-coated morphine tablets, 1 tablet orally every 4 hours for 7 days. Group II received 1 % morphine solution for injection, intramuscularly, 4 mg every 4 hours for 7 days. A Numeric Rating Scale for Pain (NRS, 0–100 mm) was used to assess the level of pain. The safety assessment was based on the collection of data on the registration of adverse events, including opioid-associated adverse effects.

Results. Enteral and parenteral morphine administration for 7 days demonstrated a statistically significant decrease in the intensity of pain syndrome in cancer patients. The use of morphine hydrochloride in tablets reduced the number of additional analgesics prescribed for cancer patients. Regarding opioid-associated adverse effects, a statistically significant difference in the incidence of constipation between two groups was observed.

Conclusion. The study showed that tablets and injectable dosage forms of morphine hydrochloride were comparable in efficacy and safety profile, thus predetermining the widespread clinical use of drugs produced by the domestic manufacturer in accordance with the “pain relief ladder”, proposed by WHO. 

About the Authors

R. A. Zukov
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovskiy
Russian Federation

MD, DSc, Head Department of Oncology and Radiation Therapy,

1, P. Zeleznyaka Street, 660022-Krasnoyarsk;

16, Smolenskaya Street, 660133-Krasnoyarsk



O. P. Bobrova
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovskiy
Russian Federation

MD, PhD, Prof,

1, P. Zeleznyaka Street, 660022-Krasnoyarsk;

16, Smolenskaya Street, 660133-Krasnoyarsk



G. N. Gildeeva
I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation
Russian Federation

MD, DSc, Professor,

8-2, Trubetskaya Street, 119992-Moscow



D. V. Butuzova
Medical Development Agency Ltd.
Russian Federation
Vasilisy Kozhinoi Street, 121096-Moscow


E. A. Ershova
Russian Pharmaceutical Company «Moscow Endocrine Plant»
Russian Federation
25, Novokhokhlovskaya Street, 109052-Moscow


References

1. Abuzarova G.R., Alekseeva G.S., Nigmatullina Z.Sh., Kuznecov S.V. Accessibility of narcotic analgetics for treatment of pain syndrome in oncology practice. Russian Journal of Pain. 2013; 3: 48–54. (in Russian).

2. Nevzorova D.V., Abuzarova G.R. Clinical guidelines: chronic pain syndrome in adult patients requiring palliative care. Therapy. 2017; 32: 69–75. (in Russian).

3. Abuzarova G.R., Alekseeva G.S., Sarmanaeva R.R., Dushakova L.V. Modern possibilities of import substitution in the treatment of pain syndrome in cancer patients. Research’n Practical Medicine Journal. 2014; 1(1): 815. (in Russian).

4. Palekhov A.V., Vvedenskaya E.S. Opioid analgesics in the therapy of chronic pain: Problems and Promises. Russian Journal of Pain. 2015; 40(3): 56–63. (in Russian).

5. Berezikova O., Usenko O., Berezikov V., Sharafutdinov M. Access to Opioids in Two Regions of Russia. Palliat. Med. 2012; 26(4): 458.

6. Dowell D., Haegerich T.M., Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016. JAMA. 2016 Apr 19; 315(15): 1624–45. doi: 10.1001/jama.2016.1464.

7. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012 Jan 22; 72(2): 181–90. doi: 10.2165/11597260-000000000-00000.

8. Lebedeva M.V., Kononova S.V. Pharmacoeconomical explanation for choosing a prolonged formulation of morphine to reducechronic pain syndrome in oncologic patients. Bashkortostan Medical Journal. 2016; 11(3(63)): 58–61. (in Russian).


Review

For citations:


Zukov R.A., Bobrova O.P., Gildeeva G.N., Butuzova D.V., Ershova E.A. EFFICACY AND SAFETY OF MORPHINE HYDROCHLORIDE IN CANCER PATIENTS WITH CHRONIC PAIN. Siberian journal of oncology. 2019;18(4):27-33. (In Russ.) https://doi.org/10.21294/1814-4861-2019-18-4-27-33

Views: 1464


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1814-4861 (Print)
ISSN 2312-3168 (Online)